These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 32232883

  • 1. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M, Enokida H.
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [Abstract] [Full Text] [Related]

  • 2. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
    Chen S, Cui L, Hu Q, Shen Y, Jiang Y, Zhao J.
    Biochem Biophys Res Commun; 2020 Sep 10; 530(1):142-148. PubMed ID: 32828276
    [Abstract] [Full Text] [Related]

  • 3. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 10; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 4. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 10; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 5. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM.
    Int J Cancer; 2014 May 15; 134(10):2322-9. PubMed ID: 24243565
    [Abstract] [Full Text] [Related]

  • 6. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
    Harada K, Miyake H, Kumano M, Fujisawa M.
    Br J Cancer; 2013 Oct 29; 109(9):2389-95. PubMed ID: 24091619
    [Abstract] [Full Text] [Related]

  • 7. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B, Edeline J, Patard JJ, Oger E, Jouan F, Boulanger G, Zerrouki S, Vigneau C, Rioux-Leclercq N.
    J Cancer Res Clin Oncol; 2012 Jun 29; 138(6):907-16. PubMed ID: 22322364
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.
    Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ.
    PLoS One; 2015 Jun 29; 10(8):e0135962. PubMed ID: 26313261
    [Abstract] [Full Text] [Related]

  • 10. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J.
    BMC Cancer; 2014 May 28; 14():376. PubMed ID: 24886512
    [Abstract] [Full Text] [Related]

  • 11. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M.
    Urol Oncol; 2012 May 28; 30(4):356-61. PubMed ID: 20207176
    [Abstract] [Full Text] [Related]

  • 12. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 May 28; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 13. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, Fang Z, Shen Z, Ding Q, Chen S.
    Oncotarget; 2017 May 02; 8(18):30151-30161. PubMed ID: 28404914
    [Abstract] [Full Text] [Related]

  • 14. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L, Maute L, Guschmann M.
    Expert Rev Anticancer Ther; 2014 Jan 02; 14(1):9-21. PubMed ID: 24313573
    [Abstract] [Full Text] [Related]

  • 15. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
    Juengel E, Makarević J, Reiter M, Mani J, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.
    Neoplasia; 2014 Apr 02; 16(4):291-300. PubMed ID: 24862756
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R, Boni JP, Ravaud A.
    Cancer Treat Rev; 2013 Nov 02; 39(7):784-92. PubMed ID: 23375248
    [Abstract] [Full Text] [Related]

  • 18. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.
    Clin Genitourin Cancer; 2014 Oct 02; 12(5):335-40. PubMed ID: 24787966
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.